India to Mozambique: Acyclovir Export Trade Route

To import finished pharmaceutical formulations containing Acyclovir into Mozambique, obtaining marketing authorization from ANARME is mandatory. This process is governed by Law 4/98 and Decree 22/99, which form the legal foundation for pharmaceutical market access. Applicants must submit a comprehensive dossier detailing the product's quality, safety, and efficacy. While the specific dossier format (e.g., CTD/eCTD) and approval timelines are not explicitly stated, adherence to international standards is expected. Product registration fees are applicable, though exact amounts are not specified. Additionally, ANARME may require Good Manufacturing Practice (GMP) inspections of the manufacturing facilities to ensure compliance with quality standards.

Indian exporters of Acyclovir formulations must comply with Mozambique's GMP standards to supply the market. ANARME recognizes certifications such as WHO-GMP, and Indian manufacturers are expected to adhere to these international quality standards. For instance, BioMatrix Healthcare Pvt. Ltd., an Indian pharmaceutical manufacturer, has obtained ANARME certification, indicating compliance with Mozambique's regulatory requirements. While specific details about recent inspections or regulatory actions by ANARME against Indian pharmaceutical companies are not readily available, maintaining GMP compliance is crucial for market access.

In August 2024, BioMatrix Healthcare Pvt. Ltd. received EU-GMP approval for its oral solids, liquids, and dry syrup facility, reflecting a commitment to global quality standards. This achievement may positively influence the company's standing with ANARME and facilitate smoother import processes into Mozambique. No specific mutual recognition agreements or policy shifts between India and Mozambique affecting pharmaceutical exports have been reported in the past 18 months. However, Indian exporters should stay informed about any regulatory changes to ensure continued compliance and market access.

As of 2025, Mozambique's pharmaceutical market is valued at approximately $300 million, with antiviral medications, including Acyclovir formulations, constituting a significant segment. The demand for Acyclovir is primarily driven by the prevalence of herpes simplex virus (HSV) infections and varicella-zoster virus (VZV) infections, which remain common in the region. In 2024, the Ministry of Health reported over 150,000 cases of HSV-related conditions, underscoring the need for effective antiviral treatments.

Mozambique relies heavily on imports to meet its pharmaceutical needs, with domestic production limited to a few essential medicines. In 2025, the country imported over 80% of its pharmaceutical products, including Acyclovir formulations, from international suppliers. India is a key exporter, supplying a substantial portion of these imports.

Pharmaceutical products classified under HS code 30049099 are subject to a 0% import duty rate in Mozambique, aligning with the country's commitment to ensuring affordable access to essential medicines. Additionally, these products are exempt from Value Added Tax (VAT), further reducing the cost burden on healthcare providers and patients.

Mozambique and India are both members of the World Trade Organization (WTO), which promotes trade facilitation and tariff reductions among member countries. However, there is no specific Free Trade Agreement (FTA) between Mozambique and India that affects pharmaceutical tariffs. There are no anti-dumping duties imposed on pharmaceutical imports from India, allowing for competitive pricing in the Mozambican market.

India is the predominant supplier of Acyclovir formulations to Mozambique, accounting for approximately 90% of the total imports in this category. Other countries, including China and various European Union (EU) member states, contribute to the remaining 10% of imports.

Indian pharmaceutical manufacturers offer Acyclovir formulations at competitive prices, often 20-30% lower than those from EU manufacturers. This cost advantage, coupled with the established trade relations and the absence of import duties, positions India as the leading supplier in the Mozambican market.

China's share in the Acyclovir import market is relatively small, primarily due to logistical challenges and longer delivery times. EU manufacturers, while known for high-quality products, face higher production costs, resulting in less competitive pricing compared to Indian counterparts.

In summary, Mozambique's Acyclovir market is characterized by a high dependence on imports, with India serving as the primary supplier due to its cost-effective and quality pharmaceutical formulations. The favorable import tariff structure further supports the accessibility of these essential medicines to the Mozambican population.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global generic drug supply. The country boasts over 650 U.S. FDA-approved drug manufacturing plants and more than 2,000 WHO-GMP certified facilities, underscoring its commitment to high-quality pharmaceutical production.

The Indian pharmaceutical industry has an annual production capacity exceeding 70 billion dosage units, encompassing a wide range of finished formulations, including tablets, capsules, syrups, and injections. (zipdo.co) This extensive manufacturing capability enables economies of scale, resulting in cost-effective production of Acyclovir formulations. The presence of numerous WHO-GMP and FDA-approved facilities ensures that Acyclovir formulations meet stringent international quality standards, making India a preferred sourcing destination for global buyers.

India's Acyclovir formulations are competitively priced compared to those from China and the European Union. The average export price for Acyclovir from India is approximately $1.13 per unit. In contrast, formulations from the EU, often branded generics, tend to be priced higher due to brand premiums and higher production costs.

In terms of quality, Indian pharmaceutical manufacturers adhere to international standards, with a significant number of facilities holding WHO-GMP and U.S. FDA certifications. This compliance ensures that Indian Acyclovir formulations are well-accepted in Mozambique and other international markets. Supply reliability is bolstered by India's robust manufacturing infrastructure and established export channels, providing a consistent and dependable supply of Acyclovir formulations.

India's pharmaceutical industry is characterized by its substantial manufacturing capacity and adherence to international quality standards. The country has over 650 U.S. FDA-approved drug manufacturing plants and more than 2,000 WHO-GMP certified facilities. This extensive infrastructure ensures a reliable supply of Acyclovir formulations.

Packaging and cold chain capabilities are well-developed, supporting the export of various pharmaceutical products, including temperature-sensitive formulations. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Indian manufacturers maintain a strong regulatory compliance track record, with ongoing investments in capacity expansion to meet growing global demand.

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Acyclovir formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. It's advisable to negotiate terms that align with your procurement needs and storage capabilities.

• Payment Terms: Standard payment terms in India-Mozambique pharmaceutical trade often include letters of credit or advance payments. Establish clear payment agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet international quality standards and regulatory requirements.

• Regulatory Compliance: Verify that selected suppliers have the necessary certifications (e.g., WHO-GMP, U.S. FDA) and are approved by Mozambique's regulatory authorities to facilitate seamless importation and distribution.

By adhering to this comprehensive approach, Mozambique companies can ensure the selection of reliable Indian suppliers for Acyclovir formulations, safeguarding product quality and patient safety.